The week in review

Eli Lilly's direct-to-consumer distribution model and the recall of Andrographis products continued to attract headlines this week  Reassurances from pharmaceutical giant Eli Lilly are doing little to ease pharmacists' concerns about the company's LillyDirect platform.   Pharmacy owner, John Jones told the AJP that the direct-to-consumer model would see patients using Mounjaro (tirzepatide) miss out on